Supported via arm's length funding from Novo Nordisk

Highlights from

EASD 2019

55th Annual Meeting of the European Association for the Study of Diabetes

Barcelona, Spain 16 - 20 September 2019

Professor Hertzel Gerstein (REWIND)

In this podcast, Professor Hertzel Gerstein, Endocrinologist at McMaster University, Canada discusses results from the REWIND trial, describing cardiovascular outcomes for patients with type 2 diabetes treated with dulaglutide and how these results compare with data from other GLP-1 receptor agonist cardiovascular outcome trials.

Professor Hertzel Gerstein’s disclosures:
Research funding: Eli Lilly, AstraZeneca, Merck, Novo Nordisk, Sanofi.
Consulting/ advisory boards/ speaker: Abbott, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck, Novo Nordisk, Janssen Pharmaceuticals, Sanofi, Kowa Pharmaceuticals, Cirius Therapeutics.


Recent advances in diabetes management

Top image: @ iStockPhoto: Kwangmoozaa

The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.

Supported by